News for Healthier Living
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates -- FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
December 7, 2024
December 21 2024December 20 2024December 19 2024December 18 2024December 17 2024December 16 2024December 15 2024December 14 2024December 13 2024December 12 2024December 11 2024December 10 2024December 9 2024December 8 2024December 7 2024
|
|
|
|
|